| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 8.32% | HC Wainwright & Co. | $2 → $1 | Maintains | Buy |
| 10/05/2023 | — | Ladenburg Thalmann | Downgrades | Buy → Neutral | |
| 08/21/2023 | 116.64% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 06/21/2023 | 333.28% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 06/16/2023 | 333.28% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 06/15/2023 | 224.96% | Chardan Capital | → $3 | Reiterates | Buy → Buy |
| 05/17/2023 | 333.28% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 04/27/2023 | 224.96% | Chardan Capital | → $3 | Reiterates | → Buy |
| 04/13/2023 | 333.28% | HC Wainwright & Co. | → $4 | Reiterates | → Buy |
| 04/03/2023 | 333.28% | HC Wainwright & Co. | → $4 | Reiterates | → Buy |
| 11/29/2022 | 333.28% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 08/11/2022 | 224.96% | Chardan Capital | $7 → $3 | Maintains | Buy |
| 05/13/2022 | 658.23% | Chardan Capital | $10 → $7 | Maintains | Buy |
| 04/01/2022 | 983.19% | Chardan Capital | $17 → $10 | Maintains | Buy |
| 11/05/2021 | 1741.42% | Chardan Capital | → $17 | Initiates Coverage On | → Buy |
| 11/02/2021 | 2391.33% | Baird | → $23 | Initiates Coverage On | → Outperform |
What is the target price for SAB Biotherapeutics (SABS)?
The latest price target for SAB Biotherapeutics (NASDAQ: SABS) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $1.00 expecting SABS to rise to within 12 months (a possible 8.32% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for SAB Biotherapeutics (SABS)?
The latest analyst rating for SAB Biotherapeutics (NASDAQ: SABS) was provided by HC Wainwright & Co., and SAB Biotherapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for SAB Biotherapeutics (SABS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SAB Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SAB Biotherapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating SAB Biotherapeutics (SABS) correct?
While ratings are subjective and will change, the latest SAB Biotherapeutics (SABS) rating was a maintained with a price target of $2.00 to $1.00. The current price SAB Biotherapeutics (SABS) is trading at is $0.92, which is out of the analyst's predicted range.